N
STJ

Natixis’s St Jude Medical STJ Stock Holding History

Natixis’s Portfolio STJ Stock Details STJ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-17,620
Closed -$1.41M – 1073
2016
Q4 		$1.41M Sell
17,620
-1,839,203
-99% -$146M 0.01% 406
2016
Q3 		$148M Buy
1,856,823
+487,841
+36% +$39.4M 1.71% 10
2016
Q2 		$107M Buy
+1,368,982
New +$97.6M 1.99% 6
2014
Q3 		– Sell
-87,669
Closed -$6.07M – 507
2014
Q2 		$6.07M Buy
+87,669
New +$5.68M 0.07% 169

Other funds holding STJ

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return
JWA
JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Natixis's STJ Position: Q1 2017 in Review

Natixis sold out of St Jude Medical (STJ) in Q1 2017, closing a stake of 17,620 shares — an estimated $1.41M sold.

Natixis first reported a position in STJ in Q2 2014 and held it in 4 quarters. The position peaked at $148M in Q3 2016. 4 funds tracked by Wall St. Rank hold STJ as of Q1 2017.

  • Natixis reported no remaining St Jude Medical position as of Q1 2017 after selling out during the quarter.
  • Natixis sold 17,620 St Jude Medical shares in Q1 2017, an estimated $1.41M.
  • Natixis first reported a position in St Jude Medical in Q2 2014 and held it in 4 quarters.
  • Natixis's St Jude Medical position peaked at $148M in Q3 2016.
  • 4 funds tracked by Wall St. Rank held St Jude Medical as of Q1 2017.

Based on Natixis's 13F filing for Q1 2017, filed 15 May 2017.